Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst Paul Matteis initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $43.
Stifel analyst Paul Matteis initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $43.